Birk Harjus S, Han Seunggu J, Butowski Nicholas A
Department of Neurological Surgery, University of California, San Francisco, CA, USA.
CNS Oncol. 2017 Jan;6(1):61-70. doi: 10.2217/cns-2016-0013. Epub 2016 Dec 21.
High-grade gliomas are aggressive brain tumors encompassing Grade III and IV classifications. Of these, glioblastoma (GB) is the most malignant with a high rate of recurrence after initial resection. Although standard treatment does exist for newly diagnosed GBs, therapeutic strategies for recurrent GB are less solidified. However, mounting evidence describes the role of re-resection, bevacizumab, chemotherapy, targeted molecular therapies, immunotherapeutic approaches and radiotherapy in recurrent GB management. This review article provides analysis of the aforementioned therapies, through assessing their effect on overall survival. Because GB tumor heterogeneity is prevalent there is a constant need to investigate therapies targeting recurrence. Studies evaluating both therapeutic targets and strategies for high-grade gliomas are and will remain invaluable.
高级别胶质瘤是侵袭性脑肿瘤，包括III级和IV级分类。其中，胶质母细胞瘤（GB）恶性程度最高，初次切除后复发率很高。虽然新诊断的GB有标准治疗方法，但复发性GB的治疗策略尚未完全确立。然而，越来越多的证据表明再次切除、贝伐单抗、化疗、靶向分子疗法、免疫治疗方法和放疗在复发性GB治疗中的作用。这篇综述文章通过评估上述疗法对总生存期的影响，对其进行了分析。由于GB肿瘤异质性普遍存在，因此一直需要研究针对复发的疗法。评估高级别胶质瘤治疗靶点和策略的研究过去是、将来也仍将是非常有价值的。
